Saurabh Chhabra, MD, MS

Associate Professor

view physician profile

Locations

Froedtert Hospital
Cancer Center - Froedtert Hospital

Specialties

Hematology
Medical Oncology

Languages

English, Hindi

Contact Information

(414) 805-0505

Education

MD - Doctor of Medicine
MS

Biography

Saurabh Chhabra, MD, is assistant professor of medicine at the Medical College of Wisconsin in the Division of Hematology and Oncology. He specializes in the management of multiple myeloma and in Blood and Marrow Transplantation for hematologic malignancies.

He is a graduate of University College of Medical Sciences, University of Delhi, India. He completed his Internal Medicine residency in 2008 and Fellowship in Hematology/Oncology in 2011, at Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ. He then went on to complete a Fellowship in Blood and Marrow Transplantation at Stanford University in Stanford, CA in 2012. Dr. Chhabra was recruited from Stanford to Charleston, SC as an Assistant Professor in Medicine, in the Division of Hematology/Oncology at Medical University of South Carolina where he was a member of the Hematologic Malignancies/BMT program. He directed the Plasma Cell Disorders clinic at MUSC and was the site Principal Investigator of several industry-sponsored and cooperative group clinical trials, including the BMT Clinical Trials Network (CTN) trials. Dr. Chhabra received the coveted “Outstanding Clinician Award” in 2015 for his services at MUSC. He joined the Froedtert & the Medical College of Wisconsin in 2016.

Research Interests

Dr. Chhabra is board-certified in Internal Medicine, Medical Oncology and Hematology. He has authored or co-authored numerous publications, including journal articles, meeting abstracts and four book chapters. His current research interests include treatment of patients with high-risk plasma cell neoplasms and allogeneic hematopoietic cell transplantation.

Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH.

(Cornell R, Hari P, Tang S, Biran N, Callander N, Chari A, Chhabra S, Fiala MA, Gahvari Z, Gandhi U, Godby K, Gupta R, Jagannath S, Jagosky M, Kang Y, Kansagra A, Kauffman M, Kodali S, Kumar SK, Lakshman A, Liedtke M, Lonial S, Ma X, Malek E, Mansour J, McGehee EF, Neppalli A, Paul B, Richardson P, Scott EC, Shacham S, Shah J, Siegel DS, Umyarova E, Usmani SZ, Varnado W, Vij R, Costa L.) Am J Hematol. 2021 01;96(1):E5-E8 PMID: 32974944 SCOPUS ID: 2-s2.0-85092920395 09/26/2020
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.

(Costa LJ, Derman BA, Bal S, Sidana S, Chhabra S, Silbermann R, Ye JC, Cook G, Cornell RF, Holstein SA, Shi Q, Omel J, Callander NS, Chng WJ, Hungria V, Maiolino A, Stadtmauer E, Giralt S, Pasquini M, Jakubowiak AJ, Morgan GJ, Krishnan A, Jackson GH, Mohty M, Mateos MV, Dimopoulos MA, Facon T, Spencer A, Miguel JS, Hari P, Usmani SZ, Manier S, McCarthy P, Kumar S, Gay F, Paiva B.) Leukemia. 2021 01;35(1):18-30 PMID: 32778736 SCOPUS ID: 2-s2.0-85089253567 08/12/2020
Prevalence and significance of sarcopenia in multiple myeloma patients undergoing autologous hematopoietic cell transplantation.

(Williams A, Baruah D, Patel J, Szabo A, Chhabra S, Dhakal B, Hari P, Janz S, Stolley M, D'Souza A.) Bone Marrow Transplant. 2021 Jan;56(1):225-231 PMID: 32732941 PMCID: PMC7855279 SCOPUS ID: 2-s2.0-85088830942 08/01/2020
Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma.

(Munshi PN, Vesole D, Jurczyszyn A, Zaucha JM, St Martin A, Davila O, Agrawal V, Badawy SM, Battiwalla M, Chhabra S, Copelan E, Kharfan-Dabaja MA, Farhadfar N, Ganguly S, Hashmi S, Krem MM, Lazarus HM, Malek E, Meehan K, Murthy HS, Nishihori T, Olin RL, Olsson RF, Schriber J, Seo S, Shah G, Solh M, Tay J, Kumar S, Qazilbash MH, Shah N, Hari PN, D'Souza A.) Cancer. 2020 Dec 01;126(23):5077-5087 PMID: 32965680 SCOPUS ID: 2-s2.0-85091306660 09/24/2020
Propylene Glycol-Free Melphalan versus PG-Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation for Myeloma.

(Monahan K, Kleman A, Thapa B, Szabo A, D'Souza A, Dhakal B, Jerkins JH, Pasquini MC, Hamadani M, Hari PN, Chhabra S.) Biol Blood Marrow Transplant. 2020 12;26(12):2229-2236 PMID: 32920204 SCOPUS ID: 2-s2.0-85092250990 09/14/2020
The Effect of Granulocyte Colony-Stimulating Factor Use on Hospital Length of Stay after Allogeneic Hematopoietic Cell Transplantation: A Retrospective Multicenter Cohort Study.

(George G, Martin AS, Chhabra S, Eapen M.) Biol Blood Marrow Transplant. 2020 12;26(12):2359-2364 PMID: 32818554 PMCID: PMC7686090 SCOPUS ID: 2-s2.0-85091241149 08/21/2020
Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma.

(Dhakal B, D'Souza A, Callander N, Chhabra S, Fraser R, Davila O, Anderson K, Assal A, Badawy SM, Berdeja J, Cerny J, Comenzo R, Chakraborty R, Peter Gale R, Kamble R, Kharfan-Dabaja MA, Krem M, Ganguly S, Janakiram M, Kansagra A, Munker R, Murthy H, Patel S, Kumar S, Shah N, Qazilbash M, Hari P.) Br J Haematol. 2020 Nov;191(3):442-452 PMID: 33094839 SCOPUS ID: 2-s2.0-85088463591 10/24/2020
Specific Class I HLA Supertypes but Not HLA Zygosity or Expression Are Associated with Outcomes following HLA-Matched Allogeneic Hematopoietic Cell Transplant: HLA Supertypes Impact Allogeneic HCT Outcomes.

(Camacho-Bydume C, Wang T, Sees JA, Fernandez-Viña M, Abid MB, Askar M, Beitinjaneh A, Brown V, Castillo P, Chhabra S, Gadalla SM, Hsu JM, Kamoun M, Lazaryan A, Nishihori T, Page K, Schetelig J, Fleischhauer K, Marsh SGE, Paczesny S, Spellman SR, Lee SJ, Hsu KC.) Biol Blood Marrow Transplant. 2020 Oct 11 PMID: 33053450 SCOPUS ID: 2-s2.0-85098109122 10/15/2020
Bronchoalveolar lavage-based COVID-19 testing in patients with cancer.

(Abid MB, Chhabra S, Buchan B, Graham MB, Abedin S, Thapa B, D'Souza A, George B, Hamadani M.) Hematol Oncol Stem Cell Ther. 2020 Oct 08 PMID: 33058787 PMCID: PMC7543702 SCOPUS ID: 2-s2.0-85092735525 10/16/2020
Autonomic nervous system control of multiple myeloma.

(Cheng Y, Sun F, D'Souza A, Dhakal B, Pisano M, Chhabra S, Stolley M, Hari P, Janz S.) Blood Rev. 2020 Aug 11:100741 PMID: 32807576 PMCID: PMC7876165 SCOPUS ID: 2-s2.0-85089534779 08/19/2020
Salvage second transplantation in relapsed multiple myeloma.

(Dhakal B, D'Souza A, Kleman A, Chhabra S, Mohan M, Hari P.) Leukemia. 2020 Aug 04 PMID: 32747684 SCOPUS ID: 2-s2.0-85088870056 08/05/2020
African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States.

(Badar T, Hari P, Dávila O, Fraser R, Wirk B, Dhakal B, Freytes CO, Rodriguez Valdes C, Lee C, Vesole DH, Malek E, Hildebrandt GC, Landau H, Murthy HS, Lazarus HM, Berdeja JG, Meehan KR, Solh M, Diaz MA, Kharfan-Dabaja MA, Callander NS, Farhadfar N, Bashir Q, Kamble RT, Vij R, Munker R, Kyle RA, Chhabra S, Hashmi S, Ganguly S, Jagannath S, Nishihori T, Nieto Y, Kumar S, Shah N, D'Souza A.) Cancer. 2020 Jan 01;127(1):82-92 PMID: 32966625 PMCID: PMC7736245 SCOPUS ID: 2-s2.0-85091313309 09/24/2020